Given that MHC class I serves as the receptor of HA-2, the interaction between RELT and MYO1G identified in our study suggests a potential mechanism by which tumor cells can evade immune recognition by CD8 + T cells upon cetuximab therapy. The gene discussed is CD8A; the disease is neoplasm.